Rx Post-Approval Duration Of Use Is Not Indicator Of Safety – FDA Editorial
Executive Summary
The postmarketing safety of prescription drugs cannot be predicted using specific time markers following approval, FDA Office of Medical Policy Director Robert Temple, MD, maintained in an editorial in the May 1 Journal of the American Medical Association